lung cancer

Oncology

ASCO 2026: Three ADC approvals in five days, with Ken Keller...

At ASCO 26, Daiichi Sankyo leaders Ken Keller and John Tsai chatted with pharmaphorum about their big year of oncology launches, halfway in.

Patients

The hidden access gap in Europe’s lung cancer hospital data

New hospital-level analysis shows a provider landscape that is more concentrated, regionally uneven & strategically complex than commercially assumed.

News

Jazz, Roche combo cleared by FDA for lung cancer

Can FDA approval of Jazz Pharma's Zepzelca in a combination regimen for extensive-stage small cell lung cancer return sales of the drug to growth?

News

Mixed data from lung cancer trials on show at WCLC

Highlights of the WCLC show include new data for AstraZeneca's Tagrisso, Summit's ivonescimab, MSD/Daiichi's I-DXd, and BMS/Systimmune's iza-bren.

Oncology

Life beyond lung cancer: Johnson & Johnson’s Breathtaking vi...

Oncology

Lung cancer lung disease 3d illustration

Innovation, real-world data, and precision medicine: Pierre ...

Ahead of ASCO 2025, Pierre Fabre charts bold progress in NSCLC with targeted therapies, real-world data, and innovative partnerships

ASCO 2026: Three ADC approvals in five days, with Ken Keller...

The hidden access gap in Europe’s lung cancer hospital data

Jazz, Roche combo cleared by FDA for lung cancer

Mixed data from lung cancer trials on show at WCLC

Life beyond lung cancer: Johnson & Johnson’s Breathtaking vi...

Innovation, real-world data, and precision medicine: Pierre ...

UK, pharma industry pilot rapid access routes for medicines

Discover a new era of healthcare panel engagement: Grounded ...

lung cancer

Editor's Picks